About Alcyone

The power of biologically-inspired engineering and precision in medicine

Alcyone Lifesciences was founded in 2010 to address the unmet needs in treatment of chronic neuropathological conditions. We are committed to developing biologically inspired and clinically relevant solutions to significantly enhance current treatment modes for patients suffering from these chronic conditions.

Meet the team

Who we are

We are a team of scientists, engineers, administrators and businesspeople dedicated to building a world-class company that improves the lives of the millions of patients worldwide coping with chronic neurological disorders.

Through innovation, a commitment to excellence, and strong key partnerships, we develop tailored solutions to address treatments of complex CNS disorders.

"We build technologies with one thing in mind - the patients. Our purpose is to tackle some of the most important and challenging problems of the brain and provide patient centric solutions to that."
- PJ Anand
Founder, President & CEO

2010

Alcyone Lifesciences, Inc. was founded to address the unmet needs in treatment of chronic neuropathological conditions.

2012

Alcyone assembles world-class scientific advisory board.

Alcyone begins development on its innovative Alcyone MEMS Cannula(AMC).

2013

Hydrocephalus Collaboration

Alcyone begins collaboration with Boston Children's Hospital to address the preeminent problem in Hydrocephalus treatment - ventricular shunt occlusion.

Alcyone MEMS Cannula (AMC) pivotal proof of concept.

2014

Preclinical signal for the ReFlow™ CSF management system.

2015

Alcyone receives FDA clearance for the Alcyone MEMS Cannula (AMC).

Preclinical development of Pulsar for intrathecal delivery.

Alcyone successfully demonstrates its AMC platform application in GBM oncolytic viral therapy.

2016

Alcyone files 510(k) premarket notification for the ReFlow™ Ventricular System.

Alcyone plans to spin off Anuncia, Inc., a patient-centric company solely focused on the treatment of Hydrocephalus, with ReFlow™ as its first product. Learn More

Alcyone remains committed to developing breakthrough technologies for the treatment of CNS disorders.

Founders & Management Team

PJ Anand
Founder, President & CEO
Adam Fleisher, MD, MAS
Co-Founder
William Olbricht, PhD
Scientific Founder
Elsa Chi Abruzzo
VP of Quality, Regulatory, & Clinical Affairs
Deep Singh
VP of Operations, Product Development, & Clinical Deployment
Andrea Jackson
VP of Corporate Development
Andrea Steenstrup
Controller

Board of Directors

PJ Anand
Founder, President & CEO
Edgar D. Jannotta, Jr.
Richard Upton
David Donabedian, PhD, MBA
Co-Founder & Independent Director
Cameron Durrant MD, DRCOG, DIPCH, MRCGP, MBA

Strategic Advisory Board

Jonathan J. Fleming
Oxford Biosciences
Todd Tomba
Roche Diabetes Care
Vasudev Anand, PhD, DABT
Toxmed Preclinical and Formulation Consultants
Franz F. Hefti, PhD
Acumen Pharmaceuticals
Bill Viney
BGR Government Affairs
Todd Zion
Akston Biosciences

Scientific Advisory Board

William Olbricht, PhD
Cornell University
Joseph R. Madsen, MD
Boston Childrens' Hospital
Harvard Medical School
Olivier Danos, PhD
Biogen
E. Antonio Chiocca, MD
Harvard Medical School
Brigham & Women's Hospital
Andres Lozano, MD, PHD, BMEDSCI, FRCSC, FRS
Toronto Western Research Institute
David Roberts, MD
Dartmouth-Hitchcock Medical Center
John Laterra, MD., PHD,
Johns Hopkins University
Sangeeta Bhatia, M.D., PHD
Koch Institute
Massachusetts Institute of Technology
Michael A. Rogawski, MD, PhD
University of California - Davis
William C. Broaddus, MD, PhD
Virginia Commonwealth University
Jaime Mata, MS, PhD
University of Virginia
Eric C. Leuthardt, MD
Washington University
Sudhakar Vadivelu, DO
Cincinnati Children's Hospital

*The Alcyone MEMS Cannula (AMC™) System, a neuro-ventricular cannula, has US Food and Drug Administration (FDA) 510(k) clearance, Health Canada Licensing, and CE Marking. It is indicated for use in the U.S. and Canada for the injection of Cytarabine or the removal of cerebrospinal fluid from the ventricles of the brain during an intracranial procedure, and approved in Europe for injection or removal of substances from the brain and/or ventricles of the brain during intracranial procedures. The AMC is a dual-lumen, MR-compatible injection and aspiration cannula and can be used with existing commercial imaging and stereotactic systems. The AMC is not intended for implant, and it is intended for single patient use only.

** The Pulsar System is not yet available for commercial use and has not yet been cleared by the FDA.

*** The ReFlow™ Ventricular System is not available for commercial use. The ReFlow™ Ventricular System is pending 510(k) clearance from the U.S. Food and Drug Administration, and CE Marking.